openPR Logo
Press release

Lipodystrophy Market Is Progressing Due To Orphan Drug Incentives And Personalized Treatment | Amryt Pharma plc, Theratechnologies Inc., Takeda Pharmaceutical Company Limited, AstraZeneca

07-21-2025 08:48 PM CET | Health & Medicine

Press release from: DataM intelligence 4 Market Research LLP

Lipodystrophy Market

Lipodystrophy Market

Global Lipodystrophy Market is expected to reach at a Significant value at a CAGR of 5.1% during the forecast period 2025-2033.

Lipodystrophy Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With a focus on emerging drug technologies, evolving treatment paradigms, and regulatory frameworks, the report delivers strategic insights to support stakeholders in navigating the rapidly advancing sector from 2025 to 2033.

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/lipodystrophy-market?ophp

Lipodystrophy refers to a group of rare disorders characterized by abnormal or degenerative conditions of the body's adipose tissue. The treatment market is limited but growing with the emergence of recombinant leptin therapies and personalized medicine. Increased awareness and genetic screening are also contributing to market development in this rare disease space.

Lipodystrophy Market Competitors Overview:

Amryt Pharma plc, Theratechnologies Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Camber Pharmaceuticals, Inc., Merck KGaA, Bristol-Myers Squibb Company, GlaxoSmithKline, and Viatris Inc. among others.

Important Industry Updates of 2023, 2024 and 2025:

☐ March 25, 2025: Theratechnologies, FDA approved the F8 formulation of tesamorelin (Egrifta WRTM) for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. This marks an important regulatory milestone, expanding therapeutic options for lipodystrophy patients

Methodology and Scope

The Lipodystrophy Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/lipodystrophy-market?ophp

Lipodystrophy Market Segments Overview:

☐ By Type (Genetic Form, Congenital Generalized Lipodystrophy (CGL), Familial Partial Lipodystrophy (FPLD), Acquired Form, Acquired Generalized Lipodystrophy (AGL), Acquired Partial Lipodystrophy (APL), High Active Antiretroviral Therapy (HAART) Induced Lipodystrophy (LD-HIV), Localized Lipodystrophy)
☐ By Treatment Type (Leptin Replacement Medication, Metreleptin, Diabetes and Insulin Resistance Treatment, Lipid-Lowering Medications, Rosuvastatin, Pravastatin, Atorvastatin, Simvastatin, Others)
☐ By Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Regional Overview for Lipodystrophy Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=lipodystrophy-market?ophp

The Report Covers:

➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.

People Also Ask:

➤ What are the current global trends in sales, production, imports, and exports within the «Keyword» market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the «Keyword» market?

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lipodystrophy Market Is Progressing Due To Orphan Drug Incentives And Personalized Treatment | Amryt Pharma plc, Theratechnologies Inc., Takeda Pharmaceutical Company Limited, AstraZeneca here

News-ID: 4112803 • Views:

More Releases from DataM intelligence 4 Market Research LLP

Global Electronic Height Gauge Market to Reach US$ 0.9B by 2030- Precision Measurement, Digital Calipers & Advanced Metrology Driving Growth
Global Electronic Height Gauge Market to Reach US$ 0.9B by 2030- Precision Measu …
Market Size and Growth The Global Electronic Height Gauge Market reached US$ 0.6 billion in 2022 and is expected to reach US$ 0.9 billion by 2030, growing with a CAGR of 3.7% during the forecast period 2024-2031. Recent Developments in Electronic Height Gauges ✅ In August 2025, Renishaw announced a new dual‐method gauging system (Equator‐X 500) plus MODUS IM Equator software, offering both absolute and comparative measurement on a single device to improve
United States LCP Films and Laminates Market Size, Share, Trends, Growth Drivers, Competitive Landscape, and Forecast (2024-2031)
United States LCP Films and Laminates Market Size, Share, Trends, Growth Drivers …
Market Size and Growth The global LCP (Liquid Crystal Polymer) Films & Laminates Market is estimated to witness significant growth during the forecast period (2024-2031), driven by increasing demand across electronics, automotive, aerospace, and industrial applications. Download Free Sample Report: https://www.datamintelligence.com/download-sample/lcp-films-and-laminates-market?Juli Recent Industry Developments United States: ✅Strong surge in LCP film demand in the U.S., driven by 5G infrastructure rollouts and increasing use in high-frequency antennas. ✅LCP manufacturers are collaborating with U.S.-based
Global Cold-Pressed Coconut Oil Market to Reach US$ 5.53B by 2031:Organic, Virgin, and Healthy Oil Trends Driving 7.5% CAGR Growth
Global Cold-Pressed Coconut Oil Market to Reach US$ 5.53B by 2031:Organic, Virgi …
Market Size and Growth Global Cold-Pressed Coconut Oil Market reached US$ 3.10 billion in 2023 and is expected to reach US$ 5.53 billion by 2031, growing with a CAGR of 7.5% during the forecast period 2024-2031. Key Development: United States: Recent Cold‐Pressed Coconut Oil Developments ✅ In October 2025, Kakaku listed COCO GARDEN's cold‐pressed, organic, no‐additive coconut oil as a top-selling 無農薬 (pesticide-free) product in Japan highlighting premiumization in domestic retail. ✅ In September
United States Industrial Cleaning Chemicals Market valuation US$ 20.07 Billion by 2031 - Exclusive Report by DataM Intelligence
United States Industrial Cleaning Chemicals Market valuation US$ 20.07 Billion b …
Leander, Texas and TOKYO, Japan - Nov. 20. 2025 Global Industrial Cleaning Chemicals Market reached US$ 47 Billion and is expected to reach US$ 66.9 Billion by 2030, growing with a CAGR of 4.5 % during the forecast period 2024-2031. As per DataM Intelligence research report. Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/industrial-cleaning-chemicals-market?praveen United States: Recent Industry Developments ✅ March 2025 - The Environmental Protection Agency (EPA) enforced stricter

All 5 Releases


More Releases for Lipodystrophy

Lipodystrophy Market Detailed Industry Report Analysis 2025-2034
Introduction Lipodystrophy is a rare and complex metabolic disorder characterized by the abnormal distribution or complete absence of body fat. Patients may present with severe insulin resistance, hypertriglyceridemia, fatty liver disease, and heightened cardiovascular risks, in addition to visible physical changes. The psychological and quality-of-life burden is substantial, making effective treatment critical. Historically, management relied on symptomatic control through insulin sensitizers, lipid-lowering drugs, and lifestyle interventions. The approval of metreleptin (a recombinant
Lipodystrophy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Lipodystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Lipodystrophy Research. Learn more about our innovative pipeline
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
HIV Associated Lipodystrophy Syndrome Market 2017-2025 | TMR Research
Global HIV Associated Lipodystrophy Syndrome Market: Snapshot HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus (HIV)-infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection. Patients have lipohypertrophy, an abnormal central fat accumulation or lipoatrophy, localized loss of fat tissue, or a mixed clinical presentations representing both. The complex morphological signs associated with lipodystrophy syndrome inhibits our understanding of the etiology
Lipodystrophy Therapeutics- Pipeline Analysis 2018 | Ionis Pharmaceuticals, Inc. …
Lipodystrophy is a rare medical condition which involves problems with fat production, usage, and storage. It is categorized into two types; congenital and acquired lipodystrophy. Download the sample report @ https://www.pharmaproff.com/request-sample/1077 Congenital lipodystrophies include congenital generalized lipodystrophy, familial partial lipodystrophy, and marfanoid progeroid lipodystrophy syndrome; while acquired lipodystrophy includes acquired partial lipodystrophy, acquired generalized lipodystrophy, centrifugal abdominal lipodystrophy, lipoatrophia annularis, localized lipodystrophy and HIV-associated lipodystrophy. Get the detailed analysis @ https://www.pharmaproff.com/report/lipodystrophy-therapeutics-pipeline-analysis The
04-27-2017 | Health & Medicine
TMR
HIV-associated Lipodystrophy Market Research Report 2017
Changes in body fat concentration, affecting people with HIV, is known as HIV-associated lipodystrophy. The exact causes of this condition is currently unknown, but research suggests that this disorder can occur either due to HIV infection or as a consequence of side effects associated with drugs used in HIV infection treatment, such as Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), etc. The lipodystrophy condition is characterized by metabolic abnormalities,